Nature Medicine, Published online: 23 June 2026; doi:10.1038/s41591-026-04462-y
Obesity drug development must move beyond an emphasis on ever-greater weight loss to prioritize tolerability, sustainable benefits and medication persistence; two recent trials exemplify this shift, with more underway.